Clinical data continues to implicate the gut microbiome in an array of indications, evidencing the vast potential as a future drug target and source of biomarkers.
We are approaching a pivotal time in the industry’s development. The global human microbiome therapeutics market is forecasted to be worth $ 1,544 million by 2027! With 27% of microbiome drugs are entering phase 2 trials. It is time to cement your foundations to ready yourself for the incoming market boom.
Microbiome Connect: Gut Therapeutics will bring you essential solutions to the array of challenges operating in the microbiome field. The event will facilitate your discussions, uniting academics, biotechs and other industry stakeholders to share their exclusive research and innovation. Hear from big pharma to understand what they look for in a partner.
